PURPOSE: To test whether intrarectal amifostine limits symptoms of radiation proctitis, measured by using the Radiation Therapy Oncology Group (RTOG) gastrointestinal (GI) toxicity score and the Expanded Prostate Cancer Index Composite (EPIC) score. METHODS AND MATERIALS: Patients with localized prostate cancer received amifostine as a rectal suspension 30-45 minutes before daily three-dimensional conformal radiation therapy. The first 18 patients received 1 g of amifostine, and the next 12 patients received 2 g. Toxicity was assessed at baseline, during treatment, and at follow-up visits by using RTOG grading and the EPIC Quality of Life (QoL) 50-item questionnaire. The Bowel Function subset of the bowel domain (EPIC-BF), which targets symptom severity, and the Bowel Bother subset of the bowel domain (EPIC-BB), which assesses QoL, were evaluated and compared with the RTOG GI toxicity score. RESULTS: Median follow-up was 30 months (range, 18-36 months). Overall, EPIC-BF and EPIC-BB scores both tracked closely with the RTOG GI toxicity score. Seven weeks after the start of radiation therapy, the incidence of RTOG Grade 2 toxicity was 33% in the 1-g group (6/18 patients) compared with 0% (0/12 patients) in the 2-g group and tended toward statistical significance (p = 0.06). A significant difference between amifostine groups was observed using the EPIC-BF score at 7 weeks (p = 0.04). A difference in EPIC-BB scores between dose groups was evident at 7 weeks (p = 0.07) and was significant at 12 months (p = 0.04). CONCLUSIONS: Higher doses of amifostine produced significant improvements in acute and late bowel QoL (up to 1 year after therapy), measured using the EPIC score.
PURPOSE: To test whether intrarectal amifostine limits symptoms of radiation proctitis, measured by using the Radiation Therapy Oncology Group (RTOG) gastrointestinal (GI) toxicity score and the Expanded Prostate Cancer Index Composite (EPIC) score. METHODS AND MATERIALS: Patients with localized prostate cancer received amifostine as a rectal suspension 30-45 minutes before daily three-dimensional conformal radiation therapy. The first 18 patients received 1 g of amifostine, and the next 12 patients received 2 g. Toxicity was assessed at baseline, during treatment, and at follow-up visits by using RTOG grading and the EPIC Quality of Life (QoL) 50-item questionnaire. The Bowel Function subset of the bowel domain (EPIC-BF), which targets symptom severity, and the Bowel Bother subset of the bowel domain (EPIC-BB), which assesses QoL, were evaluated and compared with the RTOG GI toxicity score. RESULTS: Median follow-up was 30 months (range, 18-36 months). Overall, EPIC-BF and EPIC-BB scores both tracked closely with the RTOG GI toxicity score. Seven weeks after the start of radiation therapy, the incidence of RTOG Grade 2 toxicity was 33% in the 1-g group (6/18 patients) compared with 0% (0/12 patients) in the 2-g group and tended toward statistical significance (p = 0.06). A significant difference between amifostine groups was observed using the EPIC-BF score at 7 weeks (p = 0.04). A difference in EPIC-BB scores between dose groups was evident at 7 weeks (p = 0.07) and was significant at 12 months (p = 0.04). CONCLUSIONS: Higher doses of amifostine produced significant improvements in acute and late bowel QoL (up to 1 year after therapy), measured using the EPIC score.
Authors: Vassilis E Kouloulias; John R Kouvaris; George Pissakas; Elias Mallas; Christos Antypas; John D Kokakis; George Matsopoulos; Spyros Michopoulos; Kyriaki Mystakidou; Lambros J Vlahos Journal: Int J Radiat Oncol Biol Phys Date: 2005-06-01 Impact factor: 7.038
Authors: Anurag K Singh; Cynthia Ménard; Peter Guion; Nicole L Simone; Sharon Smith; Nancy Sears Crouse; Denise J Godette; Theresa Cooley-Zgela; Linda C Sciuto; Jonathan Coleman; Peter Pinto; Paul S Albert; Kevin Camphausen; C Norman Coleman Journal: Int J Radiat Oncol Biol Phys Date: 2006-05-26 Impact factor: 7.038
Authors: M I Koukourakis; G Kyrias; S Kakolyris; C Kouroussis; C Frangiadaki; A Giatromanolaki; G Retalis; V Georgoulias Journal: J Clin Oncol Date: 2000-06 Impact factor: 44.544
Authors: Anthony L Zietman; Michelle L DeSilvio; Jerry D Slater; Carl J Rossi; Daniel W Miller; Judith A Adams; William U Shipley Journal: JAMA Date: 2005-09-14 Impact factor: 56.272
Authors: Jeff M Michalski; K Winter; James A Purdy; Carlos A Perez; Janice K Ryu; Matthew B Parliament; Richard K Valicenti; Mack Roach; Howard M Sandler; Arnold M Markoe; James D Cox Journal: Int J Radiat Oncol Biol Phys Date: 2004-03-01 Impact factor: 7.038
Authors: Vitali Alexeev; Elizabeth Lash; April Aguillard; Laura Corsini; Avi Bitterman; Keith Ward; Adam P Dicker; Alban Linnenbach; Ulrich Rodeck Journal: Mol Cancer Ther Date: 2014-11-14 Impact factor: 6.261
Authors: Rachel J Gibson; Dorothy M K Keefe; Rajesh V Lalla; Emma Bateman; Nicole Blijlevens; Margot Fijlstra; Emily E King; Andrea M Stringer; Walter J F M van der Velden; Roger Yazbeck; Sharon Elad; Joanne M Bowen Journal: Support Care Cancer Date: 2012-11-10 Impact factor: 3.603
Authors: Mary Feng; Daniel Normolle; Charlie C Pan; Laura A Dawson; Sudha Amarnath; William D Ensminger; Theodore S Lawrence; Randall K Ten Haken Journal: Int J Radiat Oncol Biol Phys Date: 2012-04-27 Impact factor: 7.038
Authors: Joseph Paul Weiner; Andrew Thomas Wong; David Schwartz; Manuel Martinez; Ayse Aytaman; David Schreiber Journal: World J Gastroenterol Date: 2016-08-21 Impact factor: 5.742
Authors: Tereza Kertesz; Markus K A Herrmann; Antonia Zapf; Hans Christiansen; Robert M Hermann; Olivier Pradier; Heinz Schmidberger; Clemens F Hess; Andrea Hille Journal: Strahlenther Onkol Date: 2009-09-12 Impact factor: 3.621